Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.

@article{Rino2006ReductionTO,
  title={Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.},
  author={Yasushi Rino and Kazuo Tarao and Souichiro Morinaga and Shinichi Ohkawa and Kaoru Miyakawa and Satoru Hirokawa and Takahiro Masaki and Norio Tarao and Norio Yukawa and Hiroyuki Saeki and Yoshinori Takanashi and Toshio Imada},
  journal={Anticancer research},
  year={2006},
  volume={26 3B},
  pages={2221-6}
}
BACKGROUND To find a way to prevent the development of hepatocellular carcinoma (HCC) from hepatitis C virus-associated liver cirrhosis (HCV-LC), an analysis of the HCV-LC patients who had received reduction therapy of the alanine aminotransferase (ALT) levels was performed. PATIENTS AND METHODS Seventy-four consecutive HCV-LC patients of Child Stage A were followed for >10 years for the development of HCC. They were divided into two groups: in group A, the reduction therapy for the ALT… CONTINUE READING